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The Case for Impulse Oscillometry in the Management of Asthma in Children and Adults 
I. Introduction 
Spirometry has traditionally been employed to evaluate lung function in children and 
adults (1).  While spirometry is of  great utility, many practitioners do not use this in their  
assessment of asthma (2), which could reflect a lack of accessibility, problems with 
interpreting results, and difficulties at the extremes of age such as in preschool children 
and  the elderly, who may not be able to perform spirometry, since it requires effort- 
dependent lung maneuvers. In addition, spirometry may be limited when clinical 
conditions do not allow it to be safely performed.  
 
In this context impulse oscillometry (IOS) has been introduced as an alternative 
technique to assess lung function with particular application to asthma. IOS is 
noninvasive, easily performed during tidal breathing and requires only minimal patient 
cooperation. IOS being effort- independent makes it feasible even in young children (3,4). 
It also obviates the problems with interpreting forced mid expiratory flow rates (FEF25-
75) which are highly volume dependent, as for example in patients who perform an 
incomplete expiratory maneuver from total lung capacity to residual volume. 
 
The challenge to discover more effective asthma treatment is essential for the clinician. 
Although inhaled corticosteroids (ICS), first line controller therapy in patients of all ages 
with persistent asthma (1), have been shown to be effective in asthma in improving control 
and reducing morbidity, a considerable number of children (5) and adults (6) may not 
respond well in terms of either spirometric parameters or clinical outcomes (7).  
 One possibility accounting for these observations recently proposed has been the under 
appreciation that the peripheral airways (PAW),  less than 2mm luminal diameter, are 
major sites of airway obstruction (8) and inflammation (9) in persistent asthma, and 
therefore the delivery of standard large particle inhaled controller therapies may be 
inadequate (10) This area of the lung so called “silent zone”, has been largely neglected 
primarily due to its inaccessibility to evaluation by previous techniques. More recently, 
newer noninvasive techniques have successfully evaluated PAW (11-15) including IOS 
which measures airway impedance Zrs, a composite of airway resistance Rrs which 
detects airway obstruction in the central and PAW, and reactance Xrs which is thought to 
reflect the elasticity of the PAW (15).  IOS has been found to have good reproducibility (3), 
and shows good correlation with previously established methods of assessing the PAW 
both in adults and older children (15-20). To our knowledge this has not been adequately 
evaluated in the preschool child. 
 
It’s been suggested that IOS could detect PAW impairment (PAI) early, before clinical 
manifestations and spirometric abnormalities occur, primarily reflecting central airway 
dysfunction which may take longer to develop obstruction(21). PAI has been shown to be 
clinically related to airway hyper- reactivity, nocturnal asthma, exacerbations, steroid- 
resistant asthma, and fatal asthma (22). However, PAI may be clinically relevant at all 
levels of asthma severity (23), and control (24,25), as well as predicting the persistence of 
childhood asthma into adulthood (26), and potential loss of lung function with age (27,28).  
 
The primary purpose of this updated review is to demonstrate clinical situations where 
IOS could provide “value added” to traditional clinical and spirometric parameters. In 
addition, we examine the applicability of commercial IOS reference values for diverse 
racial/ethnic populations, as well as assess airway reactivity, and effectiveness of 
extrafine (EF) compared to standard aerosols measured by improvement in PAW 
function. A complete search in Pub Med was performed for articles for IOS in peer 
reviewed journals. The articles included in this review were based on the expert opinion 
and previous publications by the authors. 
 
II. Measurements and Interpretation 
The forced oscillation technique (FOT) developed over 60 years ago by Dubois et al was 
the first methodology to employ superimposition of  pressure fluctuations on the airway 
over the subject’s tidal breathing to determine lung function. IOS is one type of FOT 
which delivers a square wave of pressure 5 times per second thus emitting a continuous 
spectrum of frequencies that generate a larger sample of measurements, thus providing 
more detailed characteristics of respiratory function. The IOS system (MasterScreen 
Impulse Oscillometry by CareFusion, Yorba Linda, CA or Tremolo by Thorasys, 
Montreal ,Canada ) is routinely calibrated, as suggested by the manufacturer. Testing and 
analysis is performed in accordance with ERS/ATS guidelines (29). Both lung resistance 
(Rrs) and reactance (Xrs), which reflect total pulmonary impedance (Z,) are measured 
and observed by the investigator in real-time t(s) as a function of flow volume and 
pressure for approximately 30 seconds, thus allowing the investigator to select the best 
tracings. Values of Rrs and Xrs for frequencies of 5 to 20 Hz are derived from each trial 
and stored.  An average of 3 adequate trials of R and X values are analyzed and 
graphically displayed. Reproducibility in children and adults ranges between 5-15%, but 
should not exceed 17% (3, 30), - For further technical details see two previous excellent 
reviews (3, 31). 
 
Children as young as 3 years can generally perform IOS with accurate and objective 
results. Commercially available predicted values for Rrs and Xrs are based primarily on 
height (cm) according to the equipment’s default normal reference values as 
recommended by the manufacturer based on existing reference values reported primarily 
in Caucasians (32-35). However, several recent studies suggest that these reference values 
for R5 and X5 may be appropriate across diverse populations. See section III on 
Population Based Reference Values. 
 
 PAW obstruction is reflected by increases in the frequency-dependent resistance with an 
elevated R5-R20 and AX, manifested in obstructive diseases such as asthma and COPD 
(Fig 1).  This is because the pressure waves’ signal propagating into the distal lung, 
demonstrated by R5, encounters greater resistance than the higher frequency more 
proximal R20 impulse. In addition, PAW obstruction results in loss of elastic recoil 
shown by a lower X5 and an increase in the AX, an integration index of reactance 
measure from X5 to Fres. In contrast proximal or upper airway obstruction alone exhibits 
frequency- independent elevations in Rrs across frequencies (Hz), and little to no effect 
on Xrs.  
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III. Population Based Reference Values 
 Although a representative relationship between baseline IOS parameters and physical 
characteristics (i.e., height, age, weight, etc.) of children and adults without lung disease 
has been implemented into the commercially available IOS devices and been used for 
several years, reference values as mentioned are primarily based on the data obtained 
from Caucasians (32-35). To compare reported IOS parameters obtained from diverse 
populations with commercially utilized values obtained from previously reported 
regression equations a PubMed database was used to search for suitable studies. 
Seventeen studies in healthy children (33-49) and eleven in  healthy adults (30;50-59) were 
identified and presented in Figure 2A and B (children) and Table 1 (adults). Due to 
limited data, IOS parameter values other than R5 and X5 were not available at this time. 
As presented in Figures 2 A and B the reported R5and X5 values, the most commonly 
reported IOS parameters in children and adults, show wide variations at a given height 
and age. However, there is substantial population overlap in R5 and X5 values at a given 
height, regardless of geographical location and ethnic differences. Table 2 includes mean 
(SD) of R5 and X5 values obtained from healthy adults with diverse geographical and 
ethnic backgrounds. Some R5 and X5 values in Table 2 were estimated using a 
regression equation (30;50,59) at a given height and age. For adults, both R5 and X5 values 
were similar regardless of demographic or geographical differences. Furthermore, it is 
remarkable to note that these values for R5 and X5 are comparable to those commercially 
utilized regression equations for both children and adults shown in Figures 2A and B and 
Table 1). Thus, R5 and X5 values that exceed the currently available commercial limits 
of the IOS parameters in children and adults at each age or height may suggest PAI and 
the need for step up therapy. However, further studies will be needed to clearly define 
normal limits of these IOS parameters for other ethnic and racial groups such as the 
African American population, as well for establishing universal reference values for the 
key PAW markers R5-R20 and AX. 
 
IV. Assessing Airway Reactivity  
 
A. Defining the Positive Bronchodilator Response 
The Bronchodilator Response (BDR) is a standard measure of airway reversibility which 
has traditionally been used to define the presence of asthma (1). The BDR has been 
reported to be useful in identifying asthma (60), those with uncontrolled asthma (61), ICS 
responsiveness (62), and may reflect airway remodeling (63). In adults the ATS defines a 
positive BDR as a ≥ 12% and 200ml increase in FEV1, based on the 95% confidence 
interval BDR value in the general population (64).  
 
Less is known about the magnitude effect of a short acting beta2 agonist on PAW. 
However, the PAW contains a high a density of beta2 adrenergic receptors (65), and thus 
IOS may exhibit a greater beta2 effect than spirometry, which primarily measures the 
more central large airways. The BDR assessed by IOS is demonstrated by the reduction 
of resistance Rrs including R5, frequency dependent R5-R20, and reactance (Xrs) AX 
(Figure 3). Previous studies have reported great variability in defining a clinically 
relevant BDR as expressed by IOS ranging from 8.6% (66) to over 40% (30) depending on 
whether describing the upper limits of the normal population (30) or differentiating the 
asthmatic patient from non-asthmatic controls (66). In order to clarify this further, we 
define a positive BDR as greater than the 95% confidence interval response for low 
frequency R5 in healthy children and adults. Low frequency resistance was selected since 
it is thought to reflect the caliber of PAW and is commonly used to define a positive 
BDR.  Six pediatric (34-36;66-68) studies, and 1 adult (30) study reporting the mean and 
standard deviation (SD) BDR, were analyzed.  The 95% upper limits (95% CI) was 
calculated from the mean + 1.96 residual SD. For preschool and school age children the 
mean of these BDR values was 39%, and for the single adult study 32%. These data 
suggest that a BDR response greater than a 40% decrease in R5 be considered a positive 
BDR, signifying significant airway reversibility in children and adults, but this cut-off 
may not be applicable in differentiating the asthmatic from the non-asthmatic. This 
situation is similar to our previous BDR study utilizing spirometry, which showed lower 
BDR values were more effective in identifying asthmatic children than those 
recommended by ATS guidelines. (60) 
 
B. Use of  IOS for Bronchial Challenge Testing 
Bronchial challenge testing with direct (eg methacholine or histamine) (69) or indirect 
acting (eg mannitol) (70) agents may be used in everyday clinical practice to identify the 
presence of airway hyperreactivity which is the hallmark of persistent asthma, 
particularly useful when the diagnosis of asthma is in doubt as in cases of unexplained 
cough or lack of apparent response to escalating treatment.  
Performing IOS with normal tidal breathing is much easier for patients to perform with 
repeated measurements during challenge, especially where coughing occurs due to 
bronchial irritation. When using methacholine or histamine challenge the threshold is 
conventionally measured using spirometry to determine  the provocative concentration 
(or dose) required to produce a 20% fall in FEV1 (PC20 FEV1). 
 
• Adult Studies  
18 adult patients with mild to moderate persistent asthma had methacholine and 
histamine challenges, measuring both spirometry and IOS (71). A mean 23.3 (95% 
CI 18.7-27.9%) fall in FEV1 was associated with a mean 43.5 (95% CI 29.4-
57.5%) increase in R5, all of which were significant. Corresponding data for 
histamine challenge were 25.9 (95% CI 21.0-30.8%) and 44.9 (95%CI 24.0-
65.8%). A PC20 FEV1 equated to a PC37 R5 for methacholine and PC35 R5 for 
histamine. Hence for practical purposes a PC40 R5 may be used to approximately 
extrapolate to a PC20FEV1 for either methacholine or histamine challenge.  
 
 Boudewijn et al performed a cross-sectional evaluation of symptomatic and 
asymptomatic adult patients with mild asthma who had a similar degree of 
methacholine hyper-reactivity. Patients with symptoms had worse PAW function 
(R5–R20 and X5) pre and post challenge in comparison to asymptomatic patients, 
with there being no difference in either R20 or FEV1, which primarily reflect the 
central airways (72). 
 
. Pediatric Studies    
Although less performed in children, the IOS response after methacholine 
challenge has been found useful particularly in young children. For example, 
Kalliola et al examined the relationship between methacholine sensitivity by IOS 
and asthma severity in children 3 to 8 years of age (73). They found that the 
increase in PAW, primarily R5-R20 after methacholine challenge was 
significantly higher in those children with more severe asthma as shown by 
increased exercise induced bronchospasm (EIB) and short acting beta 2 usage. 
This suggests that the change in R5-R20 following methacholine challenge could 
identify a population of more severe asthmatic children. In addition, Schultz et al 
demonstrated in 48 young asthmatic children undergoing methacholine challenge 
that the PD45 R5 showed the optimal combination of sensitivity and specificity to 
detect a PD20 FEV1(71). Furthermore, significant increases in resistance were seen 
well before an FEV1 response at lower methacholine doses, suggesting that IOS 
was more sensitive than spirometry. (74)  Free running is a more natural way of 
challenging the airway for bronchial hyper-reactivity and is highly specific for 
pediatric asthma, particularly in those who experienced exercise induced 
bronchospasm EIB (75). Exercise challenge as assessed by IOS has been shown to 
determine respiratory status in preschool children who may not be able to perform 
spirometry (76).  These studies suggest that assessing PAW reactivity by IOS is 
feasible even in young children as well as adults, may be more sensitive than 
spirometry, and more useful in detecting more severe asthma.                                                                          
 
 
V. The Clinical Value of IOS 
 
A. Pediatric Population 
Although IOS may correlate with spirometry, each is thought to measure different aspects 
of lung function, IOS assessing airway caliber, while spirometry reflects airflow 
characteristics.  In studies utilizing both IOS and spirometry, IOS has been shown to be 
more useful than spirometry in children in differentiating asthma from normal cohorts, 
particularly utilizing the BDR decrease in R5 or R10 of 20%in  preschool children,(77,78) 
and 8.6% in school age children (66).  IOS also proved more diagnostic in identifying 
uncontrolled asthmatic patients utilizing baseline values (25,36). These studies suggest that 
in children IOS detection of PAI maybe more reflective of an earlier event than central 
airway pathology in asthma identified by spirometry. This observation could have 
important therapeutic implications to suggest earlier introduction of therapy with EF ICS, 
for example.  
 
Several more recent studies have suggested a predictive role for IOS. In a longitudinal 
analysis we demonstrated in 54 children (ages 7-17 years) with mild to moderate asthma, 
who were considered to be in good control by clinical symptoms and spirometry, that R5-
R20 and AX were more predictive of loss of control 8 to 12 weeks after the initial visit 
than spirometric measures including FEF25-75.(79)  
Schultz and colleagues evaluated the value of IOS compared to spirometry and 
methacholine challenge as predictors of asthma exacerbation in children 4 to 7 years over 
a 1 year observation period.  R5 and R5-R20 were more predictive of an exacerbation, 
even at a time when the patient was asymptomatic, than FEV1, FEV1/FVC or 
methacholine challenge (21).  
Longitudinal measures suggest that irreversible changes in the lung function may develop 
before school age, and in fact may be present in the newborn in those destined to develop 
asthma (27). Decreased FEV1, and FEV1/FVC are considered key indicators of future 
exacerbation, and decreased lung function over time. Spirometry may be limited 
however, in the preschool child and reflects primarily central airway disease, while 
studies have suggested that the PAW may also play a role in the development and control 
of asthma.  Thus, Knihtila et al has recently reported that IOS findings of peripheral 
airway obstruction at ages 2- 7 years in asthmatic children were significantly related to 
abnormal post bronchodilator spirometry in those patients as adolescents , ages of 12-18 
years (28).  Based on a negative predictive value of 98% the authors concluded that 
asthmatic children with normal preschool lung function are unlikely to have decreased 
lung function in adolescence. Thus, IOS could be used by the clinician to target those 
young asthmatic children with evidence of PAI for early therapeutic intervention to 
prevent further pulmonary and clinical sequelae. Taken in totality these studies suggest 
that in children IOS may be clinically useful even when spirometry can be performed. . 
 
B. Adult Population 
In this section we consider the proportion of adult asthmatic patients who have abnormal 
IOS values, and the association with asthma severity, asthma control, and loss of asthma 
control. In tandem we compare the utility of IOS with spirometry in these adult asthma 
patients. 
 A cross sectional evaluation of 368 patients evaluated the prevalence of small airway 
obstruction with community managed persistent asthma, who were receiving steps 2-4 of 
British Thoracic Society (BTS) guidelines (80). An abnormal physiological value for 
peripheral airway resistance (R5-R20) of 0.03  kPa/L/swas defined as the upper 95%CI 
from healthy volunteers.(23) This showed that across BTS severity steps there was a high 
prevalence of peripheral airway dysfunction with 65%, 64% and 70% of abnormal values 
in mild, moderate and severe asthma, respectively. Peripheral airway resistance was 
significantly higher at step 4 than step 3 (0.12 vs 0.08 1)kPa/L/s, while no significant 
differences were observed with FEF25-75.  Hence despite a relatively well preserved 
FEV1 across BTS steps, there appears to be evidence of persistent small airways 
dysfunction which can be detected using IOS. 
 
The relationship of IOS and spirometry to asthma control as measured by the Asthma 
Control Questionnaire (ACQ) was evaluated by cross sectional analysis of 108 patients 
with uncontrolled, moderate to severe persistent asthma attending a secondary care 
clinic(20) The mean ACQ score of 2.37 was higher than the cut point of 1.5 for poor 
control. IOS measurements (R5-R20, AX, RF), but not spirometry, were significantly 
discriminatory in terms of worse control, while only R5-R20 was discriminatory for 
increased albuterol use. 
 
.  
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In a subgroup analysis, a cohort of 302 patients were then identified who had a preserved 
FEV1 (>80% predicted) to evaluate the predictive value of peripheral airways 
dysfunction defined as either R5-R20 > 0.07 kPa.l.s-1kPa/L/sor FEF25-75 
<70%. (81) These patients were then evaluated for one year pre and post the index 
measurement. In this cohort with a mean age of 40 years and an FEV1 of 97% predicted, 
the proportion across BTS steps 1-4 were 6%, 38%, 28 %, and 28% respectively. An 
abnormal value for R5-R20 in 135 patients (45%) was associated with 44(95%CI 8-66) 
% and 47 (95%CI 13-67)%  increased likelihood of oral corticosteroid and  albuterol use 
respectively, while an abnormal FEF25-75 value  in 157 (52%) patients was associated 
with a corresponding 33 (95%CI 9-60)% and  48 (95%CI 26-67)% increase, all of which 
were significant. Abnormal values for both R5-R20 and FEF25-75 in 83 patients (28%) 
were associated with  57(95%CI 17-78)%  and a 68(95%CI 39-83)% increased risk of 
oral corticosteroid and albuterol use respectively which were numerically, but not 
significantly greater than R5-R20 or FEF25-75 alone. These data suggest that IOS and 
spirometry may provide complimentary information on small airways function, 
suggesting perhaps that neither measurement should be taken in isolation. In addition, 
these studies demonstrate that IOS may be particularly useful when the FEV1 is normal. 
 
VI. Effectiveness of Impulse Oscillometry in Stratification of Inhaled Corticosteroids 
Therapy Response 
The peripheral airways of asthmatics have high receptor density of both beta 2 (65) and 
corticosteroid (82) receptors in airway structural cells and have been shown in pathological 
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studies to be a site of corticosteroid responsive eosinophilic airway inflammation and 
corticosteroid non-responsive airway remodeling (83-84). 
These observations underpin the potential value of targeting the peripheral airways with 
long acting inhaled bronchodilators (LABA) and ICS in asthma, while highlighting the 
need to develop therapies that may attenuate airway remodeling and potentially modify 
disease progression. 
 
Impulse oscillometry may be a useful biomarker of therapeutic response to inhaled 
therapies in asthma, which is underpinned by its ability to partition both central and 
peripheral airways dysfunction. In addition, the rapid proliferation of inhaled devices in 
asthma (85) with varying formulation chemistry (particle size and fine particle fraction) 
and post actuation properties (e.g. plume duration) that may influence total lung 
deposition, has created a need to develop stratified approaches to identify therapeutic 
responsiveness. A variety of radiolabelled ligand studies as well as imaging based 
simulation studies have suggested that extra-fine and SoftmistTM inhalers demonstrate 
superior deposition in the lung and peripheral airways (86-87). 
 
A variety of studies have evaluated the role of ICS with or without LABA with IOS R5-
R20 as peripheral airway outcome measures (86-90). These studies are summarized in 
Table 2, with additional information on the treatment ‘effect size’ on the peripheral 
airway R5-R20 and the standard deviation of R5-R20. 
 
It is evident that the majority of studies are open label with/without randomization and 
that few studies have been conducted in a double blind double randomized fashion. A 
number of studies have compared EF with non-EF ICS, ICS/LABA inhaled therapy (88-92). 
These studies have shown a consistent effect size, favoring EF therapy by a mean of 
0.02-0.03kPa/L/sfor R5-R20. In addition, the studies demonstrate an effect upon IOS R5-
R20 LABA (91), and ICS with or without LABA (88) when comparing EF vs non-EF 
therapy suggesting that this outcome may be representative of both bronchodilator 
sensitive and inflammatory disease in the peripheral airways. To date, studies evaluating 
IOS therapy response in children with asthma are lacking.These studies clearly suggest 
the superiority of EF ICS ± LABA in reducing PAI which should improve clinical asthma 
outcomes. What is needed now are studies that demonstrate that this is indeed the case.   
 
VII.  Limitation of IOS 
In comparison to spirometry there are several limitations of IOS that need to be addressed 
to improve the general acceptance of this tool. These include interference from upper 
airway artifacts from tongue movement or swallowing which requires coaching, expense 
of the equipment, consistent reimbursement by the insurance industry, despite the fact 
that CPT codes are currently available, interpretation of currently available reference 
values, and the need to further establish universal reference values not only for R5 and 
X5, but the major markers of PAW function R5 –R20 and AX.  
 
VIII. Conclusion  
The PAW are the major sites of airway inflammation and obstruction in asthma. IOS 
offers an in-office tool that can assess PAI even in young children, and may detect airway 
obstruction earlier than spirometry. In children, IOS may be superior to spirometry in 
determining asthma status, and predicting loss of control and exacerbations, while in 
adults it appears to be complimentary to spirometry, particularly FEF25-75 for these 
outcomes. IOS may be particularly useful when the FEV1 is normal. Commercially 
available reference values R5 and X5 seem appropriate for the diverse geographical 
populations we evaluated. Improvement in PAW obstruction as determined by R5-R20, 
appears to consistently show the superiority of EF ICS +/-LABA aerosol therapy. 
However, this effect needs to be translated into clinical outcomes. Finally, detecting PAI 
with IOS may target young asthmatics who may benefit from early therapeutic 
intervention which may prevent further pulmonary and clinical sequelae. 
 
